On June 24, Lundbeck Korea announced that they will launch new treatment for Parkinson's disease 'Azilect' in Korea
On June 24, Lundbeck Korea announced that they will launch new treatment for Parkinson's disease 'Azilect' in Korea on July 1 after a 10-year hiatus.
'Azilect' (ingredients: Rasagilin mesylate) is a second-generation selective irreversible MAO-B (monoamine oxidase type B) inhibitor, which acts a...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
